Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1983 Sep;24(3):448–449. doi: 10.1128/aac.24.3.448

5-fluorocytosine susceptibility of pathogenic fungi in the presence of allopurinol: potential for improving the therapeutic index of 5-fluorocytosine.

T M Kerkering, P M Schwartz, A Espinel-Ingroff, P J Turek, R B Diasio
PMCID: PMC185345  PMID: 6639003

Abstract

The minimal inhibitory concentration of 5-fluorocytosine in 18 pathogenic fungal isolates was not altered by either allopurinol (100 microM) or oxypurinol (100 microM). Since allopurinol at this level clinically has been demonstrated to interfere with 5-fluorouracil anabolism, thereby reducing toxicity owing to 5-fluorouracil, allopurinol may be useful in counteracting the 5-fluorouracil-induced myelotoxicity observed in patients being treated with 5-fluorocytosine without interfering with the antifungal activity of 5-fluorocytosine.

Full text

PDF
448

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennet J. E. Flucytosine. Ann Intern Med. 1977 Mar;86(3):319–321. doi: 10.7326/0003-4819-86-3-319. [DOI] [PubMed] [Google Scholar]
  2. Diasio R. B., Lakings D. E., Bennett J. E. Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity. Antimicrob Agents Chemother. 1978 Dec;14(6):903–908. doi: 10.1128/aac.14.6.903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Finch R. E., Bending M. R., Lant A. F. Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients. Br J Clin Pharmacol. 1979 Jun;7(6):613–617. doi: 10.1111/j.1365-2125.1979.tb04651.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fox R. M., Woods R. L., Tattersall M. H., Piper A. A., Sampson D. Allopurinol modulation of fluorouracil toxicity. Cancer Chemother Pharmacol. 1981;5(3):151–155. doi: 10.1007/BF00258472. [DOI] [PubMed] [Google Scholar]
  5. Hande K., Reed E., Chabner B. Allopurinol kinetics. Clin Pharmacol Ther. 1978 May;23(5):598–605. doi: 10.1002/cpt1978235598. [DOI] [PubMed] [Google Scholar]
  6. Kauffman C. A., Frame P. T. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother. 1977 Feb;11(2):244–247. doi: 10.1128/aac.11.2.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Koechlin B. A., Rubio F., Palmer S., Gabriel T., Duschinsky R. The metabolism of 5-fluorocytosine-2-14-C and of cytosine-14-C in the rat and the disposition of 5-fluorocytosine-2-14-C in man. Biochem Pharmacol. 1966 Apr;15(4):435–446. doi: 10.1016/0006-2952(66)90254-1. [DOI] [PubMed] [Google Scholar]
  8. Polak A., Eschenhof E., Fernex M., Scholer H. J. Metabolic studies with 5-fluorocytosine-6-14C in mouse, rat, rabbit, dog and man. Chemotherapy. 1976;22(3-4):137–153. doi: 10.1159/000221923. [DOI] [PubMed] [Google Scholar]
  9. Polak A., Scholer H. J. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy. 1975;21(3-4):113–130. doi: 10.1159/000221854. [DOI] [PubMed] [Google Scholar]
  10. Schwartz P. M., Dunigan J. M., Marsh J. C., Handschumacher R. E. Allopurinol modification of the toxicity and antitumor activity of 5-fluorouracil. Cancer Res. 1980 Jun;40(6):1885–1889. [PubMed] [Google Scholar]
  11. Williams K. M., Duffield A. M., Christopher R. K., Finlayson P. J. Identification of minor metabolites of 5-fluorocytosine in man by chemical ionization gas chromatography mass spectrometry. Biomed Mass Spectrom. 1981 Apr;8(4):179–182. doi: 10.1002/bms.1200080410. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES